NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates
12:25pm, Tuesday, 17'th May 2022 Zacks Investment Research
Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates
09:15pm, Monday, 16'th May 2022 Zacks Investment Research
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates
12:25pm, Thursday, 12'th May 2022 Zacks Investment Research
Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
12:05am, Friday, 06'th May 2022 GlobeNewswire Inc.
PALO ALTO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Na
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license and development partner, Sichuan Kelun-Biotech Biopharmaceutical
Why Sorrento Therapeutics Stock Shot 7% Higher Today
10:54pm, Monday, 02'nd May 2022 The Motley Fool
The company delivers some encouraging news about a COVID drug.
3 Penny Stocks to Watch During the Stock Market Crash
10:16pm, Monday, 02'nd May 2022 PennyStocks
Check these three penny stocks out as the stock market falls
The post 3 Penny Stocks to Watch During the Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Why Sorrento Therapeutics Stock Shot 7% Higher Today
06:54pm, Monday, 02'nd May 2022
The company delivers some encouraging news about a COVID drug.
3 Penny Stocks to Watch During the Stock Market Crash
06:16pm, Monday, 02'nd May 2022
Check these three penny stocks out as the stock market falls The post 3 Penny Stocks to Watch During the Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.
01:00pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies
04:46pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “
FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron
04:15pm, Monday, 25'th Apr 2022
The FDA has cleared Sorrento Therapeutics Inc's (NASDAQ: SRNE) investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and pharmacokinetics in hea
Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
01:30pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug appl
SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Execu
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
07:43pm, Tuesday, 19'th Apr 2022 The Motley Fool
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.